Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, 9500 Euclid Avenue, A30, Cleveland, Ohio, 44195, USA.
Int J Colorectal Dis. 2020 Jan;35(1):41-49. doi: 10.1007/s00384-019-03449-1. Epub 2019 Nov 23.
It is unknown if ulcerative colitis (UC) duration has an impact on outcomes of ileal pouch anal anastomosis (IPAA). The aim of the study was to compare the long-term IPAA outcomes based on preoperative UC duration.
All patients with pathologically confirmed UC who underwent IPAA were included from a prospectively maintained pouch database (1983-2017).Patient's cohort was stratified according to UC duration:< 5 years,5-10 years,10-20 years,> 20 years. UC duration was defined as time interval from date of preoperative diagnosis to colectomy date. The main outcome was Kaplan-Meier pouch survival. Secondary outcomes were pouch function and quality of life.
Out of 4502 IPAAs (1983-2016), 2797 patients were included. Treated with biologics versus 12% with UC duration > 20 years were 41% patients with UC duration < 5 years. Treated with steroids compared to shortest (34%,p < 0.001) were 54% patients with the longest disease. A total of 65% of patients with shortest disease had IPAAs performed mostly in 3 stages. Anastomotic separation and pelvic sepsis were more prevalent among shortest compared to longest disease groups. Rates of pouch-targeted fistulas, anastomotic strictures, and pouchitis were highest in longest disease group. Pouch survival was similar between groups. Multivariate analysis did not show a significant association between UC duration and pouch failure [1.05(0.97-1.1), p = 0.23].Longer UC duration was associated with increased odds of pouchitis [1.2(1.1, 1.3), p < 0.001]. Biologics agents were shown to be protective against pouchitis.
Preoperative UC duration does not increase pouch failure risk. Longer preoperative UC duration increases the pouchitis risk. Biologic agents and three-staged IPAA are protective against pouchitis and septic complications in long-term among patients with UC.
溃疡性结肠炎(UC)的病程是否会影响回肠贮袋肛管吻合术(IPAA)的结果尚不清楚。本研究旨在比较基于术前 UC 病程的长期 IPAA 结果。
从前瞻性维护的贮袋数据库(1983-2017 年)中纳入所有经病理证实的 UC 患者行 IPAA。根据 UC 病程将患者队列分层:<5 年、5-10 年、10-20 年、>20 年。UC 病程定义为术前诊断至结肠切除术的时间间隔。主要结局是贮袋存活率。次要结局为贮袋功能和生活质量。
在 4502 例 IPAA(1983-2016 年)中,纳入了 2797 例患者。与 UC 病程>20 年的患者相比,接受生物制剂治疗的患者比例为 41%,UC 病程<5 年的患者比例为 12%。与病程最短的患者相比,接受皮质类固醇治疗的患者比例最高,为 54%,UC 病程最长。病程最短的患者中有 65%接受了主要为三阶段的 IPAA。与病程最长的患者相比,最短病程的患者中吻合口分离和骨盆感染更为常见。在最长病程的患者中,贮袋靶向性瘘管、吻合口狭窄和贮袋炎的发生率最高。各组间贮袋存活率相似。多变量分析显示 UC 病程与贮袋失败之间无显著相关性[1.05(0.97-1.1),p=0.23]。UC 病程较长与贮袋炎的风险增加相关[1.2(1.1,1.3),p<0.001]。生物制剂被证明可预防贮袋炎。
术前 UC 病程不会增加贮袋失败的风险。较长的术前 UC 病程会增加贮袋炎的风险。生物制剂和三阶段 IPAA可预防 UC 患者长期发生贮袋炎和感染性并发症。